| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT04847466 Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803… |
Trial completed |
| 2026-06-02 | NCT04847466 Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803… |
date change Primary completion moved earlier: 2027-01-31 -> 2025-12-22 |
| 2026-06-02 | NCT04847466 Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803… |
date change Completion moved earlier: 2027-12-31 -> 2026-01-06 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and… | NSCLC Stage IV | Recruiting |
| Phase 2 | |||
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Glioblastoma | Recruiting |
| NCT06161545 | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head… | Stage II Squamous Cell Carcinoma of the Head and Neck | Recruiting |
| NCT07108036 | A Study to Assess Anktiva in Patients With Long Covid-19. | Long COVID | Recruiting |
| NCT07145164 | Interleukin-15 to Promote Post-ART Control of HIV | HIV | Enrolling by Invitation |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin… | Relapsed B-Cell Non-Hodgkin Lymphoma | Not Yet Recruiting |
| NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine… | Adenocarcinoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06253494 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting… | Endometrial Cancer | Recruiting |
| NCT06149481 | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine… | Metastatic Colorectal Cancer | Recruiting |